Hypertrophic cardiomyopathy laboratory findings: Difference between revisions
No edit summary |
No edit summary |
||
Line 46: | Line 46: | ||
Some patients with Hypertrophic cardiomyopathy may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication]. | Some patients with Hypertrophic cardiomyopathy may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication]. | ||
'''ESC recommendations for genetic counselling and testing''' | |||
* 1.Genetic counselling by trained professionals working within a multidisciplinary specialist team is recommended for all patients with HCM when their disease cannot be explained solely by a non-genetic cause. | |||
* 2. Genetic testing is recommended in patients fulfilling diagnostic criteria for HCM when it enables cascade genetic screening of their relatives. | |||
* 3. First degree relatives should be provided with information about the consequences of a diagnosis for life insurance, pension, occupation, sporting activities, and eligibility for fostering and adoption before they undergo genetic testing or clinical evaluation. | |||
* 4. When a definite causative genetic mutation is identified, relatives should be first genetically tested and then clinically evaluated if they are found to carry the same mutation. | |||
* 5. When genetic testing cannot be performed or fails to identify a definite mutation, first degree relatives should be offered clinical screening with an ECG and echocardiogram which is then repeated every 1-2 years between 10 and 20 years of age and then every 2-5 years thereafter. | |||
* 6. Clinical and genetic testing of children should be guided by the best interests of the child and consider potential benefits and harms such as compromised life insurance prospects. | |||
<br /> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 16:20, 16 December 2019
Hypertrophic Cardiomyopathy Microchapters |
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hypertrophic cardiomyopathy laboratory findings On the Web |
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
Risk calculators and risk factors for Hypertrophic cardiomyopathy laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of Hypertrophic cardiomyopathy.
OR
Laboratory findings consistent with the diagnosis of Hypertrophic cardiomyopathy include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with Hypertrophic cardiomyopathy.
OR
Some patients with Hypertrophic cardiomyopathy may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with Hypertrophic cardiomyopathy.
Laboratory Findings
There are no diagnostic laboratory findings associated with Hypertrophic cardiomyopathy.
OR
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of Hypertrophic cardiomyopathy.
OR
[Test] is usually normal among patients with Hypertrophic cardiomyopathy.
OR
Laboratory findings consistent with the diagnosis of Hypertrophic cardiomyopathy include:
- [Abnormal test 1]
- [Abnormal test 2]
- [Abnormal test 3]
OR
Some patients with Hypertrophic cardiomyopathy may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
ESC recommendations for genetic counselling and testing
- 1.Genetic counselling by trained professionals working within a multidisciplinary specialist team is recommended for all patients with HCM when their disease cannot be explained solely by a non-genetic cause.
- 2. Genetic testing is recommended in patients fulfilling diagnostic criteria for HCM when it enables cascade genetic screening of their relatives.
- 3. First degree relatives should be provided with information about the consequences of a diagnosis for life insurance, pension, occupation, sporting activities, and eligibility for fostering and adoption before they undergo genetic testing or clinical evaluation.
- 4. When a definite causative genetic mutation is identified, relatives should be first genetically tested and then clinically evaluated if they are found to carry the same mutation.
- 5. When genetic testing cannot be performed or fails to identify a definite mutation, first degree relatives should be offered clinical screening with an ECG and echocardiogram which is then repeated every 1-2 years between 10 and 20 years of age and then every 2-5 years thereafter.
- 6. Clinical and genetic testing of children should be guided by the best interests of the child and consider potential benefits and harms such as compromised life insurance prospects.